10 articles, transcripts, and reports
Cara Therapeutics Inc (NASDAQ: CARA) Q1 2023 earnings call dated May. 15, 2023 Corporate Participants: Matthew Murphy — Manager of Investor Relations Christopher Posner — Chief Executive Officer, President,…
Cara Therapeutics Inc (NASDAQ:CARA) Q4 2022 Earnings Call dated Mar. 06, 2023. Corporate Participants: Chris Posner — President and Chief Executive Officer Ryan Maynard — Chief Financial Officer Joana…
Cara Therapeutics Inc (NASDAQ:CARA) Q3 2022 Earnings Call dated Nov. 07, 2022. Corporate Participants: Matthew Murphy — Investor Relations Manager Christopher Posner — Chief Executive Officer, President, and Director…
Cara Therapeutics , Inc. (NASDAQ: CARA) Q2 2022 earnings call dated Aug. 08, 2022 Corporate Participants: Iris Francesconi — Chief Strategy Officer and Head of Investor Relations…
Cara Therapeutics Inc. (NASDAQ: CARA) Q1 2022 earnings call dated May. 09, 2022 Corporate Participants: Iris Francesconi — Interim Head of Investor Relations Christopher Posner — President, Chief Executive…
Cara Therapeutics, Inc. (NASDAQ: CARA) Q3 2021 earnings call dated Nov. 08, 2021 Corporate Participants: Will Gramig — Senior Analyst Derek Chalmers — Chief Executive Officer, President, and Director…
Cara Therapeutics Inc (NASDAQ:CARA) Q1 2021 earnings call dated May. 10, 2021. Corporate Participants: Jack Hildick-Smith — Investor Relations Derek Chalmers — Chief Executive Officer, President, and Director Thomas…
Cara Therapeutics Inc. (CARA) Q1 2020 earnings call dated May 11, 2020 Corporate Participants: Jack Hildick-Smith — Investor Relations Derek Chalmers — Chief Executive Officer, President, and Director Richard…
Cara Therapeutics Inc (NASDAQ: CARA) Q4 2019 Earnings Conference Call Final Transcript Corporate participants: Jack Hildick-Smith — Investor Relations Derek Chalmers — President, Director and Chief Executive Officer Richard Makara — Vice…
Cara Therapeutics’ (NASDAQ: CARA) loss widened in the third quarter of 2019, hurt by higher expenses. Cara Therapeutics posted a loss of $0.74 per share…
